Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - A pilot study

Clinical and Experimental Hypertension

Volumn 33, Issue 4, 2011, Pages 255-263

  Kanaoka, Tomohiko ^a   Tamura, Kouichi ^a   Moriya, Tatsumi ^b   Tanaka, Keiji ^b   Konno, Yusuke ^c   Kondoh, Satoshi ^c   Toyoda, Masao ^d   Umezono, Tomoya ^d   Fujikawa, Tetsuya ^e   Ohsawa, Masato ^a   Dejima, Toru ^a   Maeda, Akinobu ^a   Wakui, Hiromichi ^a   Haku, Sona ^a   Yanagi, Mai ^a   Mitsuhashi, Hiroshi ^a   Ozawa, Motoko ^a   Okano, Yasuko ^a   Ogawa, Nariaki ^a   Yamakawa, Tadashi ^f   Mizushima, Shunsaku ^e   Suzuki, Daisuke ^d   Umemura, Satoshi ^a   more..

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Ambulatory blood pressure monitoring; diabetic nephropathy; fluvastatin; glomerular filtration rate; hypertension; proteinuria; valsartan

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; FLUINDOSTATIN; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIAZIDE DIURETIC AGENT; VALSARTAN;

ADULT; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY;

ALBUMINURIA; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FATTY ACIDS, MONOUNSATURATED; FEMALE; GLOMERULAR FILTRATION RATE; HEART RATE; HUMANS; HYPERTENSION; INDOLES; KIDNEY; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TETRAZOLES; VALINE;

EID: 79959640446     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2011.583971     Document Type: Conference Paper

References (58)

1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232. (Pubitemid 35463925)
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828. (Pubitemid 28112428)
3. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000;321:412-419. (Pubitemid 30609443)
4. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000;160:1093-1100. (Pubitemid 30227018)
5. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426. (Pubitemid 32681484)
6. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-1821.
7. Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM, Pardy C, Colman P, Keech A. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011; 54:32-43.
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393. (Pubitemid 36159355)
9. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591. (Pubitemid 351214285)
10. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr., Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559. (Pubitemid 351831356)
11. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
12. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Jr., Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
13. Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
14. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006;47:699-705. (Pubitemid 43740241)
15. Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: Telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23:3174-3183.
16. Yasuda G, Kuji T, Hasegawa K, Ogawa N, Shimura G, Ando D, Umemura S. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Ren Fail 2004;26:411-418. (Pubitemid 39167619)
17. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
18. Tamura K, Tsurumi Y, Sakai M, Tanaka Y, Okano Y, Yamauchi J, Ishigami T, Kihara M, Hirawa N, Toya Y, Yabana M, Tokita Y, Ohnishi T, Umemura S. A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 2007;29:31-42.
19. Tamura K, Yamauchi J, Tsurumi-Ikeya Y, Sakai M, Ozawa M, Shigenaga A, Azuma K, Okano Y, Ishigami T, Toya Y, Yabana M, Tokita Y, Ohnishi T, Umemura S. Ambulatory blood pressure and heart rate in hypertensives with renal failure: Comparison between diabetic nephropathy and non-diabetic glomerulopathy. Clin Exp Hypertens 2008;30:33-43. (Pubitemid 351157006)
20. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: The Ohasama study. Hypertension 2000;36:901-906.
21. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation 2000;102:1536-1541.
22. Eto M, Toba K, Akishita M, Kozaki K, Watanabe T, Kim S, Hashimoto M, Ako J, Iijima K, Sudoh N, Yoshizumi M, Ouchi Y. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 2005;28:1-7. (Pubitemid 40584956)
23. Mitsuhashi H, Tamura K, Yamauchi J, Ozawa M, Yanagi M, Dejima T, Wakui H, Masuda SI, Azuma K, Kanaoka T, Ohsawa M, Maeda A, Tsurumi-Ikeya Y, Okano Y, Ishigami T, Toya Y, Tokita Y, Ohnishi T, Umemura S. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009;207:186-190.
24. Masuda S, Tamura K, Wakui H, Kanaoka T, Ohsawa M, Maeda A, Dejima T, Yanagi M, Azuma K, Umemura S. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009;32:950-955.
25. Ozawa M, Tamura K, Okano Y, Matsushita K, Ikeya Y, Masuda S, Wakui H, Dejima T, Shigenaga A, Azuma K, Ishigami T, Toya Y, Ishikawa T, Umemura S. Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin Exp Hypertens 2009;31:669-679.
26. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002;25:359-364. (Pubitemid 34752554)
27. Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000;36:894-900.
28. Parati G, Di Rienzo M, Mancia G. Neural cardiovascular regulation and 24-hour blood pressure and heart rate variability. Ann NY Acad Sci 1996;783:47-63. (Pubitemid 26372080)
29. Shintani Y, Kikuya M, Hara A, Ohkubo T, MetokiH, Asayama K, Inoue R, Obara T, Aono Y, Hashimoto T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration: The Ohasama study. J Hypertens 2007;25:1704-1710. (Pubitemid 47056579)
30. Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens 2006;24:1125-1135.
31. Kudo H, Kai H, Kajimoto H, Koga M, Takayama N, Mori T, Ikeda A, Yasuoka S, Anegawa T, Mifune H, Kato S, Hirooka Y, Imaizumi T. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 2009;54:832-838.
32. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Grassi G, Sega R. Long-term prognostic value of blood pressure variability in the general population: Results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 2007;49:1265-1270. (Pubitemid 46809367)
33. Pierdomenico SD, Di Nicola M, Esposito AL, Di Mascio R, Ballone E, Lapenna D, Cuccurullo F. Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens 2009;22:842-847.
34. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Poulter NR, Sever PS. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9: 469-480.
35. Shigenaga A, Tamura K, Dejima T, Ozawa M, Wakui H, Masuda S, Azuma K, Tsurumi-Ikeya Y, Mitsuhashi H, Okano Y, Kokuho T, Sugano T, Ishigami T, Toya Y, Uchino K, Tokita Y, Umemura S. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009;112:c31-40.
36. Spallone V, Bernardi L, Ricordi L, Solda P, Maiello MR, Calciati A, Gambardella S, Fratino P, Menzinger G. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 1993;42:1745-1752. (Pubitemid 23346411)
37. Monteagudo PT, Nobrega JC, Cezarini PR, Ferreira SR, Kohlmann O, Jr., Ribeiro AB, Zanella MT. Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients. Eur J Endocrinol 1996;135: 683-688. (Pubitemid 27062488)
38. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Satoh H, Hisamichi S. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 1997;10:1201-1207. (Pubitemid 28005341)
39. Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 1998;47:1501-1506. (Pubitemid 28396956)
40. Sturrock ND, George E, Pound N, Stevenson J, Peck GM, Sowter H. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med 2000;17:360-364. (Pubitemid 30353800)
41. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001;38:852-857. (Pubitemid 34258682)
42. Palmas W, Pickering TG, Teresi J, Schwartz JE, Moran A, Weinstock RS, Shea S. Ambulatory blood pressure monitoring and all-cause mortality in elderly people with diabetes mellitus. Hypertension 2009;53:120-127.
43. Eguchi K, Ishikawa J, Hoshide S, Pickering TG, Schwartz JE, Shimada K, Kario K. Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 2009;22:46-51.
44. Hou FF, Ren H, Owen WF, Jr., Guo ZJ, Chen PY, Schmidt AM, Miyata T, Zhang X. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004;15:1889-1896. (Pubitemid 38822069)
45. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P, Stehouwer CD. Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-Year Follow-Up Study. Diabetes 2010;59:2027-2032.
46. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003;92:785-792. (Pubitemid 36457644)
47. Jandeleit-Dahm KA, Lassila M, Allen TJ. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: Interventional studies. Ann N Y Acad Sci 2005;1043:759-766. (Pubitemid 41123970)
48. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
49. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010;375:2073-2081.
50. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-1181.
51. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:1578-1584.
52. Winnicki M, Canali C, Accurso V, Dorigatti F, Giovinazzo P, Palatini P. Relation of 24-hour ambulatory blood pressure and short-term blood pressure variability to seasonal changes in environmental temperature in stage I hypertensive subjects. Results of the Harvest Trial. Clin Exp Hypertens 1996;18:995-1012. (Pubitemid 26390206)
53. Eguchi K, Hoshide S, Hoshide Y, Ishikawa S, Shimada K, Kario K. Reproducibility of ambulatory blood pressure in treated and untreated hypertensive patients. J Hypertens 2010;28:918-924.
54. di Rienzo M, Grassi G, Pedotti A, Mancia G. Continuous vs intermittent blood pressure measurements in estimating 24-hour average blood pressure. Hypertension 1983;5:264-269. (Pubitemid 13164355)
55. Thijs L, Staessen J, Fagard R, Zachariah P, Amery A. Number of measurements required for the analysis of diurnal blood pressure profile. J Hum Hypertens 1994;8:239-244. (Pubitemid 24124538)
56. Dolan E, O'Brien E. Blood pressure variability: Clarity for clinical practice. Hypertension 2010;56:179-181.
57. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010;375:938-948.
58. Stolarz-Skrzypek K, Thijs L, Richart T, Li Y, Hansen TW, Boggia J, Kuznetsova T, Kikuya M, Kawecka-Jaszcz K, Staessen JA. Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertens Res 2010;33:757-766.